US20190262617A1 - Generation of diagnostic metrics for use in determining delivery of pacing therapy by a cardiac pacing device - Google Patents
Generation of diagnostic metrics for use in determining delivery of pacing therapy by a cardiac pacing device Download PDFInfo
- Publication number
- US20190262617A1 US20190262617A1 US15/903,550 US201815903550A US2019262617A1 US 20190262617 A1 US20190262617 A1 US 20190262617A1 US 201815903550 A US201815903550 A US 201815903550A US 2019262617 A1 US2019262617 A1 US 2019262617A1
- Authority
- US
- United States
- Prior art keywords
- left ventricular
- ejection
- determining whether
- period
- ejection period
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000000747 cardiac effect Effects 0.000 title claims abstract description 104
- 238000002560 therapeutic procedure Methods 0.000 title claims abstract description 73
- 230000002861 ventricular Effects 0.000 claims abstract description 193
- 230000004044 response Effects 0.000 claims abstract description 64
- 238000000034 method Methods 0.000 claims description 67
- 230000007423 decrease Effects 0.000 claims description 50
- 206010019280 Heart failures Diseases 0.000 claims description 47
- 230000003247 decreasing effect Effects 0.000 claims description 22
- 238000012545 processing Methods 0.000 description 69
- 230000008569 process Effects 0.000 description 17
- 230000001746 atrial effect Effects 0.000 description 14
- 230000006870 function Effects 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- 238000004891 communication Methods 0.000 description 9
- 210000002837 heart atrium Anatomy 0.000 description 7
- 230000004217 heart function Effects 0.000 description 7
- 230000005226 mechanical processes and functions Effects 0.000 description 7
- 230000000638 stimulation Effects 0.000 description 7
- 230000008602 contraction Effects 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 230000004913 activation Effects 0.000 description 5
- 230000033764 rhythmic process Effects 0.000 description 5
- 230000001934 delay Effects 0.000 description 4
- 210000005003 heart tissue Anatomy 0.000 description 4
- 210000005240 left ventricle Anatomy 0.000 description 4
- 208000001871 Tachycardia Diseases 0.000 description 3
- 238000005086 pumping Methods 0.000 description 3
- 210000005245 right atrium Anatomy 0.000 description 3
- 230000001360 synchronised effect Effects 0.000 description 3
- 206010003130 Arrhythmia supraventricular Diseases 0.000 description 2
- 206010065341 Ventricular tachyarrhythmia Diseases 0.000 description 2
- 238000013500 data storage Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000000004 hemodynamic effect Effects 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000028161 membrane depolarization Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 210000005241 right ventricle Anatomy 0.000 description 2
- 230000006794 tachycardia Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 206010047302 ventricular tachycardia Diseases 0.000 description 2
- 230000003321 amplification Effects 0.000 description 1
- 210000001992 atrioventricular node Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000004375 bundle of his Anatomy 0.000 description 1
- 238000009125 cardiac resynchronization therapy Methods 0.000 description 1
- 229940030602 cardiac therapy drug Drugs 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 210000005246 left atrium Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- HLXZNVUGXRDIFK-UHFFFAOYSA-N nickel titanium Chemical compound [Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni] HLXZNVUGXRDIFK-UHFFFAOYSA-N 0.000 description 1
- 229910001000 nickel titanium Inorganic materials 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 230000004213 regulation of atrial cardiomyocyte membrane depolarization Effects 0.000 description 1
- 230000034225 regulation of ventricular cardiomyocyte membrane depolarization Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000012781 shape memory material Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 210000000596 ventricular septum Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/362—Heart stimulators
- A61N1/3621—Heart stimulators for treating or preventing abnormally high heart rate
- A61N1/3622—Heart stimulators for treating or preventing abnormally high heart rate comprising two or more electrodes co-operating with different heart regions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/362—Heart stimulators
- A61N1/365—Heart stimulators controlled by a physiological parameter, e.g. heart potential
- A61N1/36514—Heart stimulators controlled by a physiological parameter, e.g. heart potential controlled by a physiological quantity other than heart potential, e.g. blood pressure
- A61N1/36578—Heart stimulators controlled by a physiological parameter, e.g. heart potential controlled by a physiological quantity other than heart potential, e.g. blood pressure controlled by mechanical motion of the heart wall, e.g. measured by an accelerometer or microphone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/362—Heart stimulators
- A61N1/365—Heart stimulators controlled by a physiological parameter, e.g. heart potential
- A61N1/36585—Heart stimulators controlled by a physiological parameter, e.g. heart potential controlled by two or more physical parameters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/362—Heart stimulators
- A61N1/37—Monitoring; Protecting
- A61N1/3702—Physiological parameters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/372—Arrangements in connection with the implantation of stimulators
- A61N1/37205—Microstimulators, e.g. implantable through a cannula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/372—Arrangements in connection with the implantation of stimulators
- A61N1/375—Constructional arrangements, e.g. casings
- A61N1/3756—Casings with electrodes thereon, e.g. leadless stimulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/362—Heart stimulators
- A61N1/365—Heart stimulators controlled by a physiological parameter, e.g. heart potential
- A61N1/368—Heart stimulators controlled by a physiological parameter, e.g. heart potential comprising more than one electrode co-operating with different heart regions
Landscapes
- Health & Medical Sciences (AREA)
- Cardiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Physiology (AREA)
- Hematology (AREA)
- Electrotherapy Devices (AREA)
Abstract
Description
- The disclosure herein relates to systems and methods for evaluation and adjustment of delivery of a pacing therapy by an implantable cardiac pacing device.
- During normal sinus rhythm (NSR), the heart beat is regulated by electrical signals produced by the sino-atrial (SA) node located in the right atrial wall. Each atrial depolarization signal produced by the SA node spreads across the atria, causing the depolarization and contraction of the atria, and arrives at the atrioventricular (A-V) node. The A-V node responds by propagating a ventricular depolarization signal through the bundle of His of the ventricular septum and thereafter to the bundle branches and the Purkinje muscle fibers of the right and left ventricles.
- Leadless pacemakers are used to sense electrical activity and/or deliver therapeutic pacing pulses to the heart. For some patients, one atrial pacemaker may be used in one atrium of the heart. In other patients, multiple leadless pacemakers may be used in at least one atrium and at least one ventricle of the heart. Each leadless pacemaker device typically includes two or more electrodes on its outer housing to deliver therapeutic electrical pulses and/or sense intrinsic depolarizations of the heart. Each leadless pacemaker may be positioned within a chamber of the heart and, in some examples, may be anchored to a wall of the heart via a fixation mechanism.
- Patients with heart failure are often treated with cardiac resynchronization pacing therapy delivered by a pacing device to synchronize contraction/relaxation of a heart that has become asynchronous. It is typically advantageous that parameters associated with the delivered pacing therapy for addressing instances of dyssynchrony of the heart be adjusted in order to manage better outcomes for heart failure patients. In addition, heart failure diagnostics and management are critical for managing delivery of cardiac resynchronization therapy.
- A leadless pacing device may include an integrated electromechanical sensor, such as an accelerometer, whose signal can be representative of various mechanical events that occur during the contraction/relaxation cycle of a ventricle of the patient's heart. The time-intervals between these various mechanical events are reflective of cardiac mechanical function and may potentially be used as diagnostic metrics for cardiac dyssynchrony. The present disclosure relates to an automated algorithm which can determine certain relevant time-intervals from the accelerometer signal on a beat-by-beat basis. The data may be incorporated in device diagnostics as markers of cardiac mechanical function presented, for example, as a trend-chart over time. If the markers indicate values of the metrics above or below certain thresholds consistently over a period of time, the device may transmit an alert to the clinician. The data may be also used by the device to adjust pacing therapy in patients with a leadless pacing device positioned within the left ventricle for delivering closed loop resynchronization pacing.
- As a result, the present disclosure may address parameters that can be used for managing heart failure in patients to adjust pacing therapy for desired outcomes. In this way, the accelerometer signal of the leadless pacing device provides metrics for heart failure diagnostics and heart failure management. The metrics may also be utilized for adjusting device therapy parameters in a closed loop fashion for optimal cardiac resynchronization.
- The exemplary system, device and methods described herein involve determining relevant timing parameters reflecting different intervals of mechanical events that occur during the cardiac cycle and that are sensed by an activity sensor, such as an accelerometer, located within a leadless pacing device. In one example, the leadless pacing device may be positioned within one or more chambers of a patient's heart, such as within the left ventricle of the patient, for example. The timing parameters may be determined when the pacing device determines that both the heart rate and heart rhythm are regular and are not associated with the occurrence of a tachycardia event, such as when the heart rate is less than 100 beats-per-minute (bpm), for example.
- Based upon the occurrence of either a sensed ventricular event or a paced ventricular event, or sensed ventricular beat, the pacing device may determine a window of an accelerometer signal that extends, relative to the ventricular event for a period of time, such as approximately 260 ms for example. A first peak of a rectified slope of the accelerometer signal (|d(accelerometer)/dt) within the window is determined, and the timing of the first peak of the rectified slope corresponds to a surrogate of the time indicative of early systole, i.e., early contraction of the ventricle. A second peak of the accelerometer signal is also determined within a window that begins 200 ms after the ventricular event and ends 600 ms after the ventricular event. The second peak serves as a fiducial indicative of the end of systole.
- The time period extending from the ventricular event to the first peak is identified as a surrogate measurement of a pre-ejection period (PEP) for the corresponding cardiac cycle, which is typically longer for failing/asynchronous heart function. The time period extending from the first peak to the second peak is identified as a surrogate measurement of an LV ejection time (LVET) for the corresponding cardiac cycle, which is typically longer during normal synchronized pump function and shorter for failing hearts. A ratio r=PEP/LVET may be determined as an indicator of overall cardiac function, with a PEP/LVET having a greater value being associated with higher dyssynchrony and reduced efficiency in the pumping of the heart.
- In one example, the pacing device may periodically or continuously monitor these data on a cycle by cycle basis and generate a trend plot over time showing how the three parameters, PEP, LVET and PEP/LVET vary. In another example, worsening heart failure may be determined o be occurring if two or more of the following occur:
-
- i) PEP increases by a certain threshold over the last five days, such as a greater than 20% increase, for example, or increases above a predetermined threshold value, such as 400 ms for example.
- ii) LVET decreases by a certain threshold over the last five days, such as a greater than 20% decrease, for example, or decreases below a predetermined threshold value, such as 150 ms for example.
- iii) the ratio r=PEP/LVET increases by a predetermined threshold over the last five days, such as an average increase greater than 20% for example, or increases above a predetermined threshold value, such as 0.5 for example.
- In one example, once worsening heart failure is determined, an alert may be generated by the pacing device. In another example, the pacing device may adjust pacing parameters, such as an AV delay, or a pacing rate for example, resulting in improved synchronization of markers of dyssynchrony, such as PEP increasing or the ratio of PEP/LVET increasing. In another example the pacing device may continue to auto-tune AV delays (i.e., either decreasing or increasing the AV-delay) on a cycle-by-cycle basis to bring the parameter values within certain thresholds as indicated by the markers of dyssynchrony, PEP, LVET and the ratio of PEP/LVET.
- In at least one embodiment, a method of delivering a cardiac pacing therapy may comprise delivering the cardiac pacing therapy from a cardiac pacing device; sensing a pacing event from a plurality of electrodes of the pacing device; sensing an electromechanical signal from an electromechanical sensor of the pacing device; determining a pre-ejection period in response to the sensed electromechanical signal; determining a left ventricular ejection time in response to the sensed electromechanical signal; and performing one or both of adjusting a pacing parameter setting and generating an alert in response to the determined pre-ejection period and the determined left ventricular ejection time.
- In at least one embodiment, a cardiac pacing device for delivering a cardiac therapy may include one or more electrodes for sensing a cardiac event and delivering the pacing therapy; a sensor for sensing an electromechanical signal; and a processor configured to determine a pre-ejection period in response to the sensed electromechanical signal, determine a left ventricular ejection time in response to the sensed electromechanical signal, and perform one or both of adjusting a pacing parameter setting and generating an alert in response to the determined pre-ejection period and the determined left ventricular ejection time.
- In at least one embodiment, an exemplary system may include non-transitory computer readable medium storing instructions which cause a cardiac medical device to perform a method comprising: delivering the cardiac pacing therapy from a cardiac pacing device; sensing a pacing event from a plurality of electrodes of the pacing device; sensing an electromechanical signal from an electromechanical sensor of the pacing device; determining a pre-ejection period in response to the sensed electromechanical signal; determining a left ventricular ejection time in response to the sensed electromechanical signal; and performing one or both of adjusting a pacing parameter setting and generating an alert in response to the determined pre-ejection period and the determined left ventricular ejection time.
- The above summary is not intended to describe each embodiment or every implementation of the present disclosure. A more complete understanding will become apparent and appreciated by referring to the following detailed description and claims taken in conjunction with the accompanying drawings.
-
FIG. 1 is a schematic diagram illustrating a cardiac pacing device for delivering a pacing therapy according to an example of the present disclosure. -
FIG. 2 is a conceptual diagram illustrating the example cardiac pacing device ofFIG. 1 according to an example of the present disclosure. -
FIG. 3 is a functional block diagram of an example leadless cardiac pacemaker device according to an example of the present disclosure. -
FIG. 4 is a flowchart of a method of delivering a cardiac pacing therapy according to an example of the present disclosure. -
FIG. 5 is a flowchart of a method of delivering a cardiac pacing therapy according to an example of the present disclosure. -
FIG. 6 is a graphical representation of determining markers of cardiac electromechanical function during delivery of a pacing therapy by a leadless cardiac pacing device, according to an example of the present disclosure. -
FIG. 7 is a flow chart of a method of delivering a cardiac pacing therapy according to an example of the present disclosure. -
FIG. 8 is a flow chart of a method of delivering a cardiac pacing therapy according to an example of the present disclosure. -
FIG. 9 is a flow chart of a method of delivering a cardiac pacing therapy according to an example of the present disclosure. - In the following detailed description of illustrative embodiments, reference is made to the accompanying figures of the drawing which form a part hereof, and in which are shown, by way of illustration, specific embodiments which may be practiced. It is to be understood that other embodiments may be utilized and structural changes may be made without departing from (e.g., still falling within) the scope of the disclosure presented hereby.
- Exemplary systems and methods shall be described with reference to
FIGS. 1-9 . It will be apparent to one skilled in the art that elements or processes from one embodiment may be used in combination with elements or processes of the other embodiments, and that the possible embodiments of such methods and systems using combinations of features set forth herein is not limited to the specific embodiments shown in the Figures and/or described herein. Further, it will be recognized that the embodiments described herein may include many elements that are not necessarily shown to scale. Still further, it will be recognized that timing of the processes and the size and shape of various elements herein may be modified but still fall within the scope of the present disclosure, although certain timings, one or more shapes and/or sizes, or types of elements, may be advantageous over others. - The exemplary system, device and methods described herein involve determining relevant timing parameters reflecting different intervals of mechanical events that occur during the cardiac cycle and that are sensed by an activity sensor, such as an accelerometer, located within a leadless pacing device. In one example, the leadless pacing device may be positioned within one or more chambers of a patient's heart, such as within the left ventricle of the patient, for example. The timing parameters may be determined when the pacing device determines that both the heart rate and heart rhythm are regular and are not associated with the occurrence of a tachycardia event, such as when the heart rate is less than 100 beats-per-minute (bpm), for example.
- Based upon the occurrence of either a sensed ventricular event or a paced ventricular event, or sensed ventricular beat, the pacing device may determine a window of an accelerometer signal that extends, relative to the ventricular event for a period of time, such as approximately 260 ms for example. A first peak of a rectified slope of the accelerometer signal (|d(accelerometer)/dt) within the window is determined, and the timing of the first peak of the rectified slope corresponds to a surrogate of the time indicative of early systole, i.e., early contraction of the ventricle. A second peak of the accelerometer signal is also determined within a window that begins 200 ms after the ventricular event and ends 600 ms after the ventricular event. The second peak serves as a fiducial indicative of the end of systole.
- The time period extending from the ventricular event to the first peak is identified as a surrogate measurement of a pre-ejection period (PEP) for the corresponding cardiac cycle, which is typically longer for failing/asynchronous heart function. The time period extending from the first peak to the second peak is identified as a surrogate measurement of an LV ejection time (LVET) for the corresponding cardiac cycle, which is typically longer during normal synchronized pump function and shorter for failing hearts. A ratio r=PEP/LVET may be determined as an indicator of overall cardiac function, with a PEP/LVET having a greater value being associated with higher dyssynchrony and reduced efficiency in the pumping of the heart.
- In one example, the pacing device may periodically or continuously monitor these data on a cycle by cycle basis and generate a trend plot over time showing how the three parameters, PEP. LVET and PEP/LVET vary. In another example, worsening heart failure may be determined o be occurring if two or more of the following occur:
-
- i) PEP increases by a certain threshold over the last five days, such as a greater than 20% increase, for example, or increases above a predetermined threshold value, such as 400 ms for example.
- ii) LVET decreases by a certain threshold over the last five days, such as a greater than 20% decrease, for example, or decreases below a predetermined threshold value, such as 150 ms for example.
- iii) the ratio r of the PEP to the LVET, r=PEP/LVET, increases by a predetermined threshold over the last five days, such as an average increase greater than 20% for example, or increases above a predetermined threshold value, such as 0.5 for example.
- In one example, once worsening heart failure is determined, an alert may be generated by the pacing device. In another example, the pacing device may adjust pacing parameters, such as an AV delay, or a pacing rate for example, resulting in improved synchronization if markers of dyssynchrony, such as PEP increasing or the ratio of PEP/LVET increasing. In another example the pacing device may continue to auto-tune AV delays (i.e., either decreasing or increasing the AV-delay) on a cycle-by-cycle basis to bring the parameter values within certain thresholds as indicated by the markers of dyssynchrony, PEP, LVET and the ratio of PEP/LVET.
-
FIG. 1 is a schematic diagram illustrating a cardiac pacing device for delivering a pacing therapy according to an example of the present disclosure. As illustrated inFIG. 1 , asystem 200 for use in evaluation and delivery of pacing therapy according to the present disclosure may include one or moreleadless pacemaker device 202 configured to be positioned within either aright atrium 204 of aheart 206 of apatient 208, within aright ventricle 210 of thepatient 208, or both, as illustrated inFIG. 1 . Theleadless pacemaker device 202 may be configured to monitor electrical activity of the patient's 208heart 206 and/or provide electrical therapy to theheart 206. -
FIG. 2 is a conceptual diagram illustrating the example cardiac pacing device ofFIG. 1 according to an example of the present disclosure. As illustrated inFIG. 2 , theleadless pacemaker device 202 includes ahousing 220,fixation tines 222, aproximal electrode 224 and adistal electrode 226. Thehousing 220 may have a pill-shaped cylindrical form factor in some examples. Thefixation tines 222 are configured to connect (e.g., anchor)device 202 toheart 206, and may be fabricated from a shape memory material, such as Nitinol. In some examples, thefixation tines 222 may connect one or bothleadless pacemaker device 202 to theheart 206 within one or both of thechambers heart 206, as illustrated inFIG. 1 . In another example, thefixation tines 222 may be configured to anchor a singleleadless pacemaker device 202 to theheart 206 within only theright atrium 204. Although theleadless pacemaker device 202 includes a plurality offixation tines 222 that are configured to anchor theleadless pacemaker device 202 to cardiac tissue in theright atrium 204, theleft atrium 210, or both, it is contemplated that a leadless device according to the present disclosure may be fixed to cardiac tissue using other types of fixation mechanisms. - The
leadless pacemaker device 202 may include one or more electrodes for sensing electrical activity of theheart 206 and/or delivering electrical stimulation to theheart 206. While theleadless pacemaker device 202 shown includes twoelectrodes leadless pacemaker device 202 in other examples.Electrode 226 may be referred to as a “tip electrode,” andelectrode 224 may be referred to as a “ring electrode.” Thefixation tines 222 may anchor theleadless pacemaker device 202 to cardiac tissue such that thetip electrode 226 maintains contact with the cardiac tissue. Thering electrode 224 may be located on thehousing 220. For example, thering electrode 224 may be a cylindrical electrode that wraps around thehousing 220. Although thering electrode 224 is illustrated as being a cylindrical electrode that wraps around thehousing 220, thering electrode 224 may include other geometries. In some examples, thehousing 220 may be formed from a conductive material. In these examples, thehousing 220 may act as an electrode of theleadless pacemaker device 202. - The
housing 220 houses electronic components of theleadless pacemaker device 202. Electronic components may include any discrete and/or integrated electronic circuit components that implement analog and/or digital circuits capable of producing the functions attributed to theleadless pacemaker device 202 described herein. For example, thehousing 220 may house electronic components that sense electrical activity viaelectrodes electrodes housing 220 may also include memory that includes instructions that, when executed by one or more processing circuits housed within thehousing 220, cause theleadless pacemaker device 202 to perform various functions attributed to theleadless pacemaker device 202 herein. Thehousing 220 may also house sensors that sense physiological conditions of thepatient 208, such as an accelerometer and/or a pressure sensor. - In some examples, the
housing 220 may house a communication module that enables theleadless pacemaker device 202 to communicate with other electronic devices, such as aprogrammer 212 or other external patient monitor. In some examples, thehousing 220 may house an antenna for wireless communication. Thehousing 220 may also include a power source, such as a battery. Electronic components included within thehousing 220 are described in further detail hereinafter. -
FIG. 3 is a functional block diagram of an example leadless cardiac pacemaker device according to an example of the present disclosure.FIG. 3 shows a system including aleadless pacemaker device 202 positioned in theatrium 204 of theheart 206, aleadless pacemaker device 202 positioned within theventricle 210 of theheart 206, and aprogrammer 212 that may be used to program one or bothleadless pacemaker device 202 and/or to retrieve data from one or bothleadless pacemaker device 202. Eachleadless pacemaker device 202 may include a processor orprocessing module 230, memory 232 asignal generator module 234, anelectrical sensing module 236, acommunication module 238, asensor 240, and a power source 242. The power source 242 may include a battery, e.g., a rechargeable or non-rechargeable battery. - The modules included in the
leadless pacemaker device 202 represent functionality that may be included in each of theleadless pacemaker devices 202, and may include any discrete and/or integrated electronic circuit components that implement analog and/or digital circuits capable of producing the functions attributed to the modules herein. For example, the modules may include analog circuits, e.g., amplification circuits, filtering circuits, and/or other signal conditioning circuits. The modules may also include digital circuits, e.g., combinational or sequential logic circuits, memory devices, etc. Memory may include any volatile, non-volatile, magnetic, or electrical media, such as a random access memory (RAM), read-only memory (ROM), non-volatile RAM (NVRAM), electrically-erasable programmable ROM (EEPROM), Flash memory, or any other memory device. Furthermore, memory may include instructions that, when executed by one or more processing circuits, cause the modules to perform various functions attributed to the modules herein. - The functions attributed to the modules herein may be embodied as one or more processors, hardware, firmware, software, or any combination thereof. Depiction of different features as modules is intended to highlight different functional aspects, and does not necessarily imply that such modules must be realized by separate hardware or software components. Rather, functionality associated with one or more modules may be performed by separate hardware or software components, or integrated within common or separate hardware or software components.
- The
processing module 230 may communicate with thememory 232. Thememory 232 may include computer-readable instructions that, when executed by theprocessing module 230, cause theprocessing module 230 to perform the various functions attributed to theprocessing module 230 herein. Thememory 232 may include any volatile, non-volatile, magnetic, or electrical media, such as RAM, ROM, NVRAM, EEPROM, Flash memory, or any other digital media. For example, thememory 232 may include pacing instructions and values, such as the baseline atrial pacing rate, the baseline atrial pacing interval and the baseline AV interval. The pacing instructions and values may be updated by the programmer 212 (FIG. 1 ). Pacing instructions included in thememory 232 may cause theleadless pacemaker device 202 to operate as described herein. - The
processing module 230 may communicate with thesignal generator module 234 and theelectrical sensing module 236. Thesignal generator module 234 and theelectrical sensing module 236 are electrically coupled to theelectrodes electrical sensing module 236 is configured to monitor signals from theelectrodes heart 206. Thesignal generator module 234 is configured to deliver electrical stimulation to one or both of theatrium 204 of theheart 206 and theventricle 210 of theheart 206 via theelectrodes - The
processing module 230 may control signal thesignal generator module 234 to generate and deliver electrical stimulation to one or both of theatrium 204 of theheart 206 and theventricle 210 of theheart 206 via theelectrodes processing module 230 may control thesignal generator module 234 to deliver electrical stimulation therapy according to one or more atrial or ventricular therapy programs including pacing instructions and values, which may be stored in thememory 232. - The
electrical sensing module 236 may include circuits that acquire electrical signals. Electrical signals acquired by theelectrical sensing module 236 may include intrinsic cardiac electrical activity, such as intrinsic atrial and/or intrinsic ventricular cardiac electrical activity. Theelectrical sensing module 236 may filter, amplify, and digitize the acquired electrical signals to generate raw digital data. Theprocessing module 230 may receive the digitized data generated by theelectrical sensing module 236. In some examples, theprocessing module 230 may perform various digital signal processing operations on the raw data, such as digital filtering. - The
processing module 230 may sense cardiac events based on the data received from theelectrical sensing module 236. For example, theprocessing module 230 may sense atrial events based on the data received from theelectrical sensing module 236. In some examples, theprocessing module 230 may sense ventricular activation based on the data received from theelectrical sensing module 236. For example, theprocessing module 230 may detect FFRWs indicative of ventricular activation based on the data received from theelectrical sensing module 236. - The
sensor 240 may comprise at least one of a variety of different sensors. For example, thesensor 240 may comprise at least one of a pressure sensor, a heart sounds sensor, and an accelerometer. Thesensor 240 may generate signals that indicate at least one of an activity level of thepatient 208, a hemodynamic pressure, and heart sounds. Theprocessing module 230 may detect, for example, an activity level of thepatient 208 based on a sensed accelerometer signal, a hemodynamic pressure signal, and a heart sounds signal based on the signals generated by thesensor 240. - The
communication module 238 may include any suitable hardware (e.g., an antenna), firmware, software, or any combination thereof for communicating with another device, such as theprogrammer 212 or a patient monitor. Under the control of theprocessing module 230, thecommunication module 238 may receive downlink telemetry from and send uplink telemetry to other devices, such as the programmer 212 (FIG. 1 ) or a patient monitor, with the aid of an antenna included in thecommunication module 238. As described herein, a leadless pacing system may coordinate pacing of theheart 206 based on sensed cardiac electrical and/or mechanical activity without establishment of a communication link between theleadless pacemaker devices 202. Accordingly, thecommunication module 238 is not required to include functionality that provides for communication between theleadless pacemaker devices 202. - The
programmer 212 may be a handheld computing device, desktop computing device, a networked computing device, etc. Theprogrammer 212 may include a computer-readable storage medium having instructions that cause a processor of theprogrammer 212 to provide the functions attributed to theprogrammer 212 in the present disclosure. One or both of theleadless pacemaker devices 202 may wirelessly communicate with theprogrammer 212. For example, theleadless pacemaker devices 202 may transfer data to theprogrammer 212 and may receive data from theprogrammer 212. Theprogrammer 212 may also wirelessly program and/or wirelessly charge theleadless pacemaker devices 202. - Data retrieved from the
leadless pacemaker devices 202 using theprogrammer 212 may include cardiac EGMs stored by theleadless pacemaker devices 202 that indicate electrical activity of theheart 206 and marker channel data that indicates the occurrence and timing of sensing, diagnosis, and therapy events associated with theleadless pacemaker devices 202. Data transferred to theleadless pacemaker devices 202 using theprogrammer 212 may include, for example, operational programs and/or settings for theleadless pacemaker devices 202 that cause theleadless pacemaker devices 202 to operate as described herein. - The
processing module 230 may control atrial pacing timing based on the detection of ventricular activation events in a variety of different ways. The manner in which theprocessing module 230 controls atrial pacing timing may depend on when a ventricular activation event occurs relative to the atrial event that preceded the ventricular activation event. In other words, the manner in which theprocessing module 230 controls atrial pacing timing may depend on when processing module detects a FFRW or an S1 heart sound relative to the atrial event that preceded the detected FFRW or the detected S1 heart sound. -
FIG. 4 is a flowchart of a method of delivering a cardiac pacing therapy according to an example of the present disclosure. As illustrated inFIG. 4 , a method of delivering a cardiac pacing therapy according to an example of the present disclosure may include initially delivering a pacing therapy viaelectrodes pacing device 202,Block 300, during a time when processingmodule 230 of thepacing device 202 determines that the current rate and rhythm of the patient's heart is regular and not presently exhibiting atrial or ventricular tachyarrhythmia, such as when the current heart rate is less than 100 bpm for example. During delivery of the initial pacing therapy, thepacing device 202 senses a far-field cardiac signal viaelectrodes Block 302, such as an accelerometer signal sensed viasensor 240. Theprocessing module 230 determines, based on the sensed far-field signal, when a ventricular paced (V-Pace) beat occurs,Block 304. Once a V-pace beat is determined to occur, theprocessing module 230 determines one or more markers of cardiac mechanical function from the sensed electromechanical signal. For example, theprocessing module 230 may determine a pre-ejection period (PEP) associated with the current delivered V-pace beat,Block 306, and a left ventricular ejection time (LVET) associated with the current delivered V-pace beat,Block 308. The determined initial PEP and initial LVET are then stored in thememory 232 of thepacing device 202,Block 310. -
FIG. 5 is a flowchart of a method of delivering a cardiac pacing therapy according to an example of the present disclosure. As illustrated inFIG. 5 , once theprocessing module 230 determines the initial markers of cardiac electromechanical function, PEP and LVET, during a time when processingmodule 230 of thepacing device 202 determines that the current rate and rhythm of the patient's heart is regular and not presently exhibiting atrial or ventricular tachyarrhythmia, thepacing device 202 subsequently delivers a pacing therapy using initial pacing parameters associated with the pacing therapy delivered during the initial determination of the markers, such as an initial pacing rate and an initial AV interval,Block 320. - During subsequent delivery of the pacing therapy, the
pacing device 202 senses a far-field cardiac signal viaelectrodes Block 322, such as an accelerometer signal sensed fromsensor 240. Theprocessing module 230 determines, based on the far-field signal, when a pacing event, such as a ventricular paced (V-Pace) beat occurs,Block 324. Once a V-pace beat is determined to occur, theprocessing module 230 determines a pre-ejection period (PEP) associated with the current sensed V-pace beat,Block 326, a left ventricular ejection time (LVET) associated with the current sensed V-pace beat,Block 328, and updates trends based on the current determined PEP and LVET,Block 330. Theprocessing module 230 then determines, based on the current PEP and LVET, whether dyssynchrony is occurring,Block 332. If dyssynchrony is determined to be occurring, Yes inBlock 332, theprocessing module 230 adjusts one or more of the pacing parameters of the pacing therapy,Block 334, such as an AV-delay or a pacing rate, for example. - In addition to determining whether dyssynchrony is indicated or determined to occur,
Block 332, theprocessing module 230 may also determine whether worsening heart failure is being indicated based on the current PEP and LVET,Block 336. If worsening heart failure is indicated, Yes inBlock 336, an alert may be generated by theprocessing module 230,Block 338, and the process is repeated for the next beat,Block 320, using the adjusted parameter setting,Block 334, that was adjusted if dyssynchrony was determined to be occurring for the current beat, Yes inBlock 332, and using the current, non-adjusted parameter settings if dyssynchrony was not determined to be occurring for the current beat, No inBlock 332. On the other hand, if worsening heart failure is not indicated, No inBlock 336, an alarm is not generated and the process is repeated for the next beat,Block 320, using the adjusted parameter setting,Block 334, that was adjusted if dyssynchrony was determined to be occurring for the current beat, Yes inBlock 332, and using the current, non-adjusted parameter settings if dyssynchrony was not determined to be occurring for the current beat, No inBlock 332. - While both the determination of dyssynchrony,
Block 332 and the determination of worsening heart failure,Block 336, are included in theFIG. 5 , it is understood, that, in one example, during monitoring of the markers of cardiac mechanical function, i.e., PEP and LVET, theprocessing module 230 may periodically or continuously generate a trend plot over time indicative of the variation in the markers over time, and only perform the alerting of the patient or a clinician when worsening heart failure is determined to occur. In another example, theprocessing module 230 may only periodically or continuously adjust one or more settings of pacing parameters, such as AV-delay or pacing rate, to deliver improved resynchronization if the markers indicate dyssynchrony so as to bring the values of the pacing parameters within certain desired thresholds. In another example, theprocessing module 230 may perform both the generation of the alert if worsening heart failure is indicated and the adjusting of the one or more pacing parameters of the delivered pacing therapy if dyssynchrony is determined to occur based on the trend data. -
FIG. 6 is a graphical representation of determining markers of cardiac electromechanical function during delivery of a pacing therapy by a leadless cardiac pacing device, according to an example of the present disclosure. As illustrated inFIG. 6 , during delivery of the initial pacing therapy viaelectrodes processing module 230 of thepacing device 202 determines a near-field signal 400 sensed by sensing electrodes of the pacing device, and anEM signal 402 sensed by an EM sensor of the pacing device. Theprocessing module 230 identifies timing of the occurrence of a ventricular pace (VP)event 404 from the near-field signal 400 and determines atime window 406 extending a predetermined time period from the sensedVP event 404. In one example, the predetermined time period oftime window 406 may be approximately 260 ms. - In addition, the
processing module 230 determines a rectifiedderivative signal 408 of theEM signal 402 and determines timing indicative of the occurrence of early systole by determining a maximum 410 of the rectifiedderivative signal 408 that occurs within thetime window 406. In addition, theprocessing module 230 determines timing indicative of the occurrence of the end of systole by determining a maximum 412 of theaccelerometer signal 402 that occurs during a second time window having astart point 414 located apredetermined distance 416 from the sensed V-pace event 404 and that extends a predetermined time period from thestart point 414. In one example, thestart point 414 may be located 200 ms from the V-pace event 404 and the second time window may extend a predetermined time period of 600 ms from thestart point 414 of the second time window. - In this way, during initial delivery of pacing therapy determines one or more marker of cardiac mechanical function from the sensed electromechanical signal. For example, once the V-
pace event 404 is identified, and the maximum 410 of the rectifiedderivative signal 408 and the maximum 412 of theaccelerometer signal 402 are determined relative to the V-pace event 404, theprocessing module 230 may determine a pre-ejection period (PEP) 418 extending between the V-pace event 404 and the maximum 410 of the rectifiedderivative signal 408, and a left ventricular ejection time (LVET) 420 extending from the maximum 410 of the rectifiedderivative signal 408 to the maximum 412 of theaccelerometer signal 402. The determined initial pre-ejection period (PEP) 418 and initial left ventricular ejection time (LVET) 420 are then stored in thememory 232 of thepacing device 202. -
FIG. 7 is a flow chart of a method of delivering a cardiac pacing therapy according to an example of the present disclosure. As described above, in one example, during monitoring of the markers of cardiac mechanical function, i.e., PEP and LVET, theprocessing module 230 may periodically or continuously generate a trend plot over time indicative of the variation in the markers over time, and only perform the generation of the alert if worsening heart failure is determined to be occurring. In another example, theprocessing module 230 may only periodically or continuously adjust one or more settings of pacing parameters, such as AV-delay or pacing rate, by either increasing or decreasing the parameter setting to deliver improved resynchronization if the markers indicate dyssynchrony, so as to bring the values of the pacing parameters within certain desired thresholds. In another example, theprocessing module 230 may perform both the generating of the alert of worsening heart failure and the adjusting of the one or more pacing parameters of the delivered pacing therapy based on the updated trend data. - For example, as illustrated in
FIGS. 6 and 7 , once the initial pre-ejection period (PEP) 418 and initial left ventricular ejection time (LVET) 420 have been determined and stored, described above, thepacing device 202 subsequently delivers a pacing therapy having the initial pacing parameters settings associated with the pacing therapy delivered by thepacing device 202 during the determination of the initial pre-ejection period (PEP) 418 and initial left ventricular ejection time (LVET) 420, described above. Theprocessing module 230 of the pacing 202 determines, on a beat-by-beat basis, the pre-ejection period (PEP) 418 and initial left ventricular ejection time (LVET) 420 associated with each subsequently sensed V-pace event 404,Block 500, and stores the determined current pre-ejection period (PEP) 418 and initial left ventricular ejection time (LVET) 420 for each sensed V-pace event 404. Theprocessing module 230 then updates trend data over time using the currentdetermined PEP 418 andLVET 420 in such a way as to be indicative of how thePEP 418 and LVET 420 have varied over time. - Based on the updated trended data, including the current pre-ejection period (PEP) 418 and initial left ventricular ejection time (LVET) 420 data, the
processing module 230 determines whether there is a predetermined increase in thePEP 418, such as a greater than 20 percent increase on average, over a predetermined number of days, such as 5 days, for example,Block 502. If there is an increase in thePEP 418, Yes inBlock 502, indicating dyssynchrony, the pacing device may adjust one or more pacing parameters of the pacing therapy,Block 504, such as the AV-delay or pacing rate, for example. In addition, theprocessing module 230 determines whether there is both an increase in thecurrent PEP 418 and a decrease in the currentdetermined LVET 420 over a predetermined number of days, such as 5 days for example,Block 506. If there is both an increase in thecurrent PEP 418 and a decrease in the currentdetermined LVET 420, Yes inBlock 506, changes in trend data are determined to be satisfied,Block 508, and therefore worsening heart failure is indicated. - In response to the indication of worsening heart failure, an alert may be generated, and the process is repeated for the next beat,
Block 512, using the adjusted parameter setting,Block 504, that was adjusted if the predetermined increase in thePEP 418 was determined to occur for the current sensed V-pace beat 404, Yes inBlock 502. On the other hand, the process is repeated for thenext beat Block 512 using the current, non-adjusted parameter settings if the predetermined increase in thePEP 418 was not determined to occur for the current sensed V-pace beat 404, No inBlock 502. - If there is not both an increase in the
current PEP 418 and a decrease in the currentdetermined LVET 420, No inBlock 506, theprocessing module 230 determines a ratio of thePEP 418 and theLVET 420,Block 514, updates the ratio of thedetermined PEP 418 and theLVET 420 over multiple sensed V-pace events, and determines whether there is an increase in the ratio of thePEP 418 and theLVET 420,Block 516, indicative of dyssynchrony. In one example, an increase in the ratio of PEP to LVET indicative of dyssynchrony may be determined to occur if the ratio increases by a predetermined threshold over a predetermined number of days. For example, an increase in the ratio may be determined to occur if the ratio increases by more than 20 percent over five days. In another example, an increase in the ratio may be determined to occur if the ratio is greater than a predetermined threshold, such as 0.5, for example. - If an increase in the ratio of the
PEP 418 and theLVET 420 is not determined to occur, No inBlock 516, the process is repeated for the next beat,Block 512, using the adjusted parameter setting,Block 504, that was adjusted if the predetermined increase in thePEP 418 was determined to occur for the current sensed V-pace beat 404, Yes inBlock 502. On the other hand, the process is repeated for thenext beat Block 512 using the current, non-adjusted parameter settings if the predetermined increase in thePEP 418 was not determined to occur for the current sensed V-pace beat 404, No inBlock 502. - If an increase in the ratio of the
PEP 418 and theLVET 420 is determined to occur, Yes inBlock 516, theprocessing module 230 may adjust one or more pacing parameters of the pacing therapy,Block 518, such as the AV-delay or pacing rate, for example, and a determination is made as to whether there is either an increase in thePEP 418 or a decrease in theLVET 420,Block 520. If there is not one of an increase in thePEP 418 or a decrease in theLVET 420, No inBlock 520, heart failure is not indicated and the process is repeated for the next beat,Block 512, using the current, non-adjusted parameter settings, i.e., without any parameter adjustment having been made for the current sensed V-pace event 404. - If there is either an increase in the
PEP 418 or a decrease in theLVET 420, Yes inBlock 520, changes in trend data are determined to be satisfied,Block 508, and therefore worsening heart failure is indicated. In response to the indication of worsening heart failure, an alert may be generated, and the process is repeated for the next beat,Block 512, using the adjusted parameter setting,Block 504, that was adjusted if the predetermined increase in thePEP 418 was determined to occur for the current sensed V-pace beat 404, Yes inBlock 502. On the other hand, the process is repeated for thenext beat Block 512 using the current, non-adjusted parameter settings if the predetermined increase in thePEP 418 was not determined to occur for the current sensed V-pace beat 404, No inBlock 502. - In this way, based upon the occurrence of either a sensed ventricular event or a paced ventricular event, or sensed ventricular beat, the pacing device may determine a window of an accelerometer signal that extends, relative to the ventricular event for a period of time, such as approximately 260 ms for example. A first peak of a rectified slope of the accelerometer signal (|d(accelerometer)/dt) within the window is determined, and the timing of the first peak of the rectified slope corresponds to a surrogate of the time indicative of early systole, i.e., early contraction of the ventricle. A second peak of the accelerometer signal is also determined within a window that begins 200 ms after the ventricular event and ends 600 ms after the ventricular event. The second peak serves as a fiducial indicative of the end of systole.
- The time period extending from the ventricular event to the first peak is identified as a surrogate measurement of a pre-ejection period (PEP) for the corresponding cardiac cycle, which is typically longer for failing/asynchronous heart function. The time period extending from the first peak to the second peak is identified as a surrogate measurement of an LV ejection time (LVET) for the corresponding cardiac cycle, which is typically longer during normal synchronized pump function and shorter for failing hearts. A ratio r=PEP/LVET, which serves as an indicator of overall cardiac function, i.e., a greater ratio value being associated with increased dyssynchrony and reduced efficiency, may be determined as an indicator of overall cardiac function, with a PEP/LVET having a greater value being associated with higher dyssynchrony and reduced efficiency in the pumping of the heart.
- In one example, the pacing device may periodically or continuously monitor these data on a cycle by cycle basis and generate a trend plot over time showing how the three parameters, PEP, LVET and PEP/LVET vary. In another example, worsening heart failure may be determined to be occurring if two or more of the following occur:
-
- i) PEP increases by a certain threshold over the last five days, such as a greater than 20% increase, for example, or increases above a predetermined threshold value, such as 400 ms for example.
- ii) LVET decreases by a certain threshold over the last five days, such as a greater than 20% decrease, for example, or decreases below a predetermined threshold value, such as 150 ms for example.
- iii) the ratio r=PEP/LVET increases by a predetermined threshold over the last five days, such as an average increase greater than 20% for example, or increases above a predetermined threshold value, such as 0.5 for example.
- In one example, once worsening heart failure is determined, an alert may be generated by the pacing device. In another example, the
processing module 230 may adjust pacing parameters, such as an AV delay, or a pacing rate for example, resulting in improved synchronization of markers of dyssynchrony, if either thePEP 418 is determined to be increasing or the ratio of PEP/LVET is determined to be increasing. In this way, thepacing device 202 may continue to auto-tune AV delays (i.e., either decreasing or increasing the AV-delay) on a cycle-by-cycle basis to bring the parameter values within certain thresholds as indicated by the markers of dyssynchrony, PEP, LVET and the ratio of PEP/LVET. -
FIG. 8 is a flow chart of a method of delivering a cardiac pacing therapy according to an example of the present disclosure. While in the example method of delivering a cardiac pacing therapy described inFIG. 7 includes both adjusting pacing parameters when dyssynchrony is determined to occur and generating an alarm when worsening heart failure is determined, it is understood, that, in one example, theprocessing module 230 may periodically or continuously generate a trend plot over time indicative of the variation in the markers of cardiac mechanical function, i.e., PEP and LVET, over time, and perform only the generation of the alert if worsening heart failure determined to be occurring. For example, as illustrated inFIGS. 6 and 8 , once the initial pre-ejection period (PEP) 418 and initial left ventricular ejection time (LVET) 420 have been determined and stored, described above, thepacing device 202 subsequently delivers a pacing therapy having the initial pacing parameters settings associated with the pacing therapy delivered by thepacing device 202 during the determination of the initial pre-ejection period (PEP) 418 and initial left ventricular ejection time (LVET) 420, described above. Theprocessing module 230 determines, on a beat-by-beat basis, the pre-ejection period (PEP) 418, the left ventricular ejection time (LVET) 420,Block 540, and the ratio of thePEP 412 andLVET 420,Block 542, associated with each subsequently sensed V-pace event 404, and updates trend data,Block 544, using the currentdetermined PEP 418 andLVET 420 in such a way as to be indicative of how thePEP 418, theLVET 420 and a ratio of the PEP and LVET have varied over time. - Based on the updated trended data,
Block 544, including the current pre-ejection period (PEP) 418 and initial left ventricular ejection time (LVET) 420 data, theprocessing module 230 determines whether the pre-ejection period (PEP) 418 is increasing, whether the left ventricular ejection time (LVET) 420 is decreasing, and whether the ratio of thePEP 418 and theLVET 420 is increasing over multiple sensed V-pace events,Block 544. Theprocessing module 230 determines whether heart failure is occurring,Block 546, based on whether at least two of an increase in the PEP, a decrease in the LVET and an increase in the ratio of thePEP 418 and theLVET 420 are occurring, indicative of dyssynchrony. - In one example, an increase in the ratio of PEP to LVET may be determined to occur if the ratio increases by a predetermined threshold over a predetermined number of days. For example, an increase in the ratio may be determined to occur if the ratio increases by more than 20 percent over five days. In another example, an increase in the ratio may be determined to occur if the ratio is greater than a predetermined threshold, such as 0.5, for example. An increase in PEP may be determined to be occurring if there is a predetermined increase in the
PEP 418, such as a greater than 20 percent increase on average, over a predetermined number of days, such as 5 days, for example. In another example, an increase in PEP may be determined to be occurring if the PEP increases above a predetermined threshold, such as 400 ms, for example. A decrease in LVET may be determined to be occurring if there is a predetermined decrease in the currentdetermined LVET 420, such as a greater than 20 percent decrease on average, over a predetermined number of days, such as 5 days for example. In another example, a decrease in LVET may be determined to be occurring if the LVET decreases below a predetermined threshold, such as 150 ms, for example. - If at least two of an increase in the PEP, a decrease in the LVET and an increase in the ratio of the
PEP 418 and theLVET 420 are not determined to occur and therefore heart failure is not indicated, No inBlock 546, the process is repeated for the next beat,Block 548. If at least two of an increase in the PEP, a decrease in the LVET and an increase in the ratio of thePEP 418 and theLVET 420 are determined to occur and therefore heart failure is indicated, Yes inBlock 546, theprocessing module 230 may generate an alarm,Block 550, and the process is repeated for the next beat,Block 548. - In this way, worsening heart failure may be determined to be occurring if two or more of the following occur:
-
- i) PEP increases by a certain threshold over the last five days, such as a greater than 20% increase, for example, or increases above a predetermined threshold value, such as 400 ms for example.
- ii) LVET decreases by a certain threshold over the last five days, such as a greater than 20% decrease, for example, or decreases below a predetermined threshold value, such as 150 ms for example.
- iii) the ratio r=PEP/LVET increases by a predetermined threshold over the last five days, such as an average increase greater than 20% for example, or increases above a predetermined threshold value, such as 0.5 for example.
-
FIG. 9 is a flow chart of a method of delivering a cardiac pacing therapy according to an example of the present disclosure. As illustrated inFIGS. 6 and 9 , once the initial pre-ejection period (PEP) 418 and initial left ventricular ejection time (LVET) 420 have been determined and stored, described above, thepacing device 202 subsequently delivers a pacing therapy having the initial pacing parameters settings associated with the pacing therapy delivered by thepacing device 202 during the determination of the initial pre-ejection period (PEP) 418 and initial left ventricular ejection time (LVET) 420, described above. Theprocessing module 230 determines, on a beat-by-beat basis, the pre-ejection period (PEP) 418, the left ventricular ejection time (LVET) 420, and the ratio of thePEP 412 andLVET 420,Block 560, associated with each subsequently sensed V-pace event 404, and updates trend data,Block 562, using the currentdetermined PEP 418 andLVET 420 in such a way as to be indicative of how thePEP 418 and a ratio of the PEP and LVET have varied over time. - Based on the updated trended data,
Block 562, including the current pre-ejection period (PEP) 418 and initial left ventricular ejection time (LVET) 420 data, theprocessing module 230 determines, for the current sensed V-pace event 404, whether there is a predetermined increase in thePEP 418,Block 564. If there is an increase in thePEP 418, Yes inBlock 564, indicating dyssynchrony, theprocessing module 230 may adjust one or more pacing parameters of the pacing therapy,Block 566, such as the AV-delay or pacing rate, for example, and the process is repeated for the next beat,Block 568. - If there is not an increase in the
PEP 418, No inBlock 564, theprocessing module 230 determines whether the ratio of thePEP 418 to theLVET 420 has increased,Block 570. If an increase in the ratio of thePEP 418 to theLVET 420 is not determined to occur, No inBlock 570, the process is repeated for the next beat,Block 568. If an increase in the ratio of thePEP 418 to theLVET 420 is determined to occur, Yes inBlock 570, indicating dyssynchrony, theprocessing module 230 may adjust one or more pacing parameters of the pacing therapy,Block 566, such as the AV-delay or pacing rate, for example, and the process is repeated for the next beat,Block 568. In this way, theprocessing module 230 may adjust pacing parameters, such as an AV delay, or a pacing rate for example, resulting in improved synchronization of markers of dyssynchrony, if either thePEP 418 is determined to be increasing,Block 564, or the ratio of PEP/LVET is determined to be increasing,Block 570. As a result, thepacing device 202 may continue to auto-tune AV delays (i.e., either decreasing or increasing the AV-delay) on a cycle-by-cycle basis to bring the parameter values within certain thresholds as indicated by the markers of dyssynchrony, PEP and the ratio of PEP/LVET. - In one example, an increase in the ratio of PEP to LVET may be determined to occur if the ratio increases by a predetermined threshold over a predetermined number of days. For example, an increase in the ratio may be determined to occur if the ratio increases by more than 20 percent over five days. In another example, an increase in the ratio may be determined to occur if the ratio is greater than a predetermined threshold, such as 0.5, for example. An increase in PEP may be determined to be occurring if there is a predetermined increase in the
PEP 418, such as a greater than 20 percent increase on average, over a predetermined number of days, such as 5 days, for example. In another example, an increase in PEP may be determined to be occurring if the PEP increases above a predetermined threshold, such as 400 ms, for example. - The techniques described in this disclosure, such as those attributed to the
pacing device 202, including theprocessing module 230, and/or various constituent components, may be implemented, at least in part, in hardware, software, firmware, or any combination thereof. For example, various aspects of the techniques may be implemented within one or more processors, including one or more microprocessors, DSPs, ASICs, FPGAs, or any other equivalent integrated or discrete logic circuitry, as well as any combinations of such components, embodied in programmers, such as physician or patient programmers, stimulators, image processing devices, or other devices. The term “module,” “processor,” or “processing circuitry” may generally refer to any of the foregoing logic circuitry, alone or in combination with other logic circuitry, or any other equivalent circuitry. - Such hardware, software, and/or firmware may be implemented within the same device or within separate devices to support the various operations and functions described in this disclosure. In addition, any of the described units, modules, or components may be implemented together or separately as discrete but interoperable logic devices. Depiction of different features as modules or units is intended to highlight different functional aspects and does not necessarily imply that such modules or units must be realized by separate hardware or software components. Rather, functionality associated with one or more modules or units may be performed by separate hardware or software components, or integrated within common or separate hardware or software components.
- When implemented in software, the functionality ascribed to the systems, devices and techniques described in this disclosure may be embodied as instructions on a computer-readable medium such as RAM, ROM, NVRAM, EEPROM, FLASH memory, magnetic data storage media, optical data storage media, or the like. The instructions may be executed by one or more processors to support one or more aspects of the functionality described in this disclosure.
- This disclosure has been provided with reference to illustrative embodiments and is not meant to be construed in a limiting sense. As described previously, one skilled in the art will recognize that other various illustrative applications may use the techniques as described herein to take advantage of the beneficial characteristics of the apparatus and methods described herein. Various modifications of the illustrative embodiments, as well as additional embodiments of the disclosure, will be apparent upon reference to this description.
- A method of delivering a cardiac pacing therapy, comprising:
-
- delivering the cardiac pacing therapy from a cardiac pacing device;
- sensing a pacing event from a plurality of electrodes of the pacing device;
- sensing an electromechanical signal from an electromechanical sensor of the pacing device;
- determining a pre-ejection period in response to the sensed electromechanical signal;
- determining a left ventricular ejection time in response to the sensed electromechanical signal; and
- performing one or both of adjusting a pacing parameter setting and generating an alert in response to the determined pre-ejection period and the determined left ventricular ejection time.
- The method of
embodiment 1, further comprising: -
- determining a maximum of a rectified derivative of the EM signal within a first time window extending a predetermined time period from the sensed pacing event; and
- determining a maximum of the EM signal within a second time window extending from a second window start point positioned a predetermined distance from the sensed pacing event, wherein the pre-ejection period is determined in response to a time period extending between the sensed pacing event and the maximum of the rectified derivative of the EM signal, and the left ventricular ejection time is determined in response to a time period extending between the second window start point and the maximum of the EM signal.
- The method of any of
embodiments 1 to 2, wherein the first window extends approximately 260 ms from the sensed pacing event, the second window start point is positioned approximately 200 ms from the sensed pacing event and the second window extends approximately 600 ms from the second window start point. - The method of any of embodiments 1-3, further comprising:
-
- determining trend data associated with the pre-ejection period, the left ventricular ejection time and a ratio of the pre-ejection period and the left ventricular ejection time for a plurality of the sensed cardiac events;
- determining whether the pre-ejection period is increasing;
- determining whether the ratio of the pre-ejection period and the left ventricular ejection time is increasing; and
- adjusting delivery of the cardiac pacing therapy in response to one of determining the pre-ejection period is increasing and determining the ratio of the pre-ejection period and the left ventricular ejection time is increasing.
- The method of any of embodiments 1-4, wherein determining whether the pre-ejection period increases comprises one of determining whether the pre-ejection period increases by greater than a predetermined percentage over a predetermined number of days and determining whether the pre-ejection period increases above a predetermined numerical threshold, and wherein determining whether the ratio of the pre-ejection period increases comprises one of determining whether the ratio of the pre-ejection period and the left ventricular ejection time increases by greater than a predetermined percentage over a predetermined number of days and determining whether the ratio of the pre-ejection period and the left ventricular ejection time increases above a predetermined numerical threshold.
- The method of any of embodiments 1-5, further comprising:
-
- determining trend data associated with the pre-ejection period, the left ventricular ejection time and a ratio of the pre-ejection period and the left ventricular ejection time for a plurality of the sensed cardiac events;
- determining whether the pre-ejection period is increasing;
- determining whether the left ventricular ejection time is decreasing;
- determining whether the ratio of the pre-ejection period and the left ventricular ejection time is increasing;
- determining whether heart failure is indicated in response to determining at least two of the pre-ejection period determined to be increasing, the left ventricular ejection time determined to be decreasing, and the ratio of the pre-ejection period and the left ventricular ejection time determined to be increasing; and
- generating an alert in response to heart failure being indicated.
- The method of any of embodiments 1-6, wherein determining whether the pre-ejection period increases comprises one of determining whether the pre-ejection period increases by greater than a predetermined percentage over a predetermined number of days and determining whether the pre-ejection period increases above a predetermined numerical threshold, wherein determining whether the left ventricular ejection time decreases comprises one of determining whether the left ventricular ejection time decreases by greater than a predetermined percentage over a predetermined number of days and determining whether the left ventricular ejection time decreases above a predetermined numerical threshold, and wherein determining whether the ratio of the pre-ejection period increases comprises one of determining whether the ratio of the pre-ejection period and the left ventricular ejection time increases by greater than a predetermined percentage over a predetermined number of days and determining whether the ratio of the pre-ejection period and the left ventricular ejection time increases above a predetermined numerical threshold.
- The method of any of embodiments 1-7, further comprising:
-
- determining trend data associated with the pre-ejection period, the left ventricular ejection time and a ratio of the pre-ejection period and the left ventricular ejection time for a plurality of the sensed cardiac events;
- determining whether the pre-ejection period is increasing;
- determining whether the left ventricular ejection time is decreasing;
- determining whether the ratio of the pre-ejection period and the left ventricular ejection time is increasing;
- determining whether heart failure is indicated in response to determining at least two of the pre-ejection period determined to be increasing, the left ventricular ejection time determined to be decreasing, and the ratio of the pre-ejection period and the left ventricular ejection time determined to be increasing;
- adjusting delivery of the cardiac pacing therapy in response to one of determining the pre-ejection period is increasing and determining the ratio of the pre-ejection period and the left ventricular ejection time is increasing; and
- generating an alert in response to heart failure being indicated.
- The method of any of embodiments 1-8, wherein determining whether the pre-ejection period increases comprises one of determining whether the pre-ejection period increases by greater than a predetermined percentage over a predetermined number of days and determining whether the pre-ejection period increases above a predetermined numerical threshold, wherein determining whether the left ventricular ejection time decreases comprises one of determining whether the left ventricular ejection time decreases by greater than a predetermined percentage over a predetermined number of days and determining whether the left ventricular ejection time decreases above a predetermined numerical threshold, and wherein determining whether the ratio of the pre-ejection period increases comprises one of determining whether the ratio of the pre-ejection period and the left ventricular ejection time increases by greater than a predetermined percentage over a predetermined number of days and determining whether the ratio of the pre-ejection period and the left ventricular ejection time increases above a predetermined numerical threshold.
- The method of any of embodiments 1-9, wherein the cardiac pacing device comprises a leadless pacemaker device and the sensed pacing event comprises a ventricular pacing event.
- A cardiac pacing device for delivering a cardiac pacing therapy, comprising:
-
- one or more electrodes for sensing a cardiac event and delivering the pacing therapy;
- a sensor for sensing an electromechanical signal; and
- a processor configured to determine a pre-ejection period in response to the sensed electromechanical signal, determine a left ventricular ejection time in response to the sensed electromechanical signal, and perform one or both of adjusting a pacing parameter setting and generating an alert in response to the determined pre-ejection period and the determined left ventricular ejection time.
- The device of embodiment 11, wherein the processor is configured to determine a maximum of a rectified derivative of the EM signal within a first time window extending a predetermined time period from the sensed pacing event, and determine a maximum of the EM signal within a second time window extending from a second window start point positioned a predetermined distance from the sensed pacing event, wherein the pre-ejection period is determined in response to a time period extending between the sensed pacing event and the maximum of the rectified derivative of the EM signal, and the left ventricular ejection time is determined in response to a time period extending between the second window start point and the maximum of the EM signal.
- The device of any of embodiments 11-12, wherein the first window extends approximately 260 ms from the sensed pacing event, the second window start point is positioned approximately 200 ms from the sensed pacing event and the second window extends approximately 600 ms from the second window start point.
- The device of any of embodiments 11-13, wherein the processor is configured to determine trend data associated with the pre-ejection period, the left ventricular ejection time and a ratio of the pre-ejection period and the left ventricular ejection time for a plurality of the sensed cardiac events, determine whether the pre-ejection period is increasing, determine whether the ratio of the pre-ejection period and the left ventricular ejection time is increasing, and adjust delivery of the cardiac pacing therapy in response to one of determining the pre-ejection period is increasing and determining the ratio of the pre-ejection period and the left ventricular ejection time is increasing.
- The device of any of embodiments 11-14, wherein determining whether the pre-ejection period increases comprises one of determining whether the pre-ejection period increases by greater than a predetermined percentage over a predetermined number of days and determining whether the pre-ejection period increases above a predetermined numerical threshold, and wherein determining whether the ratio of the pre-ejection period increases comprises one of determining whether the ratio of the pre-ejection period and the left ventricular ejection time increases by greater than a predetermined percentage over a predetermined number of days and determining whether the ratio of the pre-ejection period and the left ventricular ejection time increases above a predetermined numerical threshold.
- The device of any of embodiments 11-15, wherein the processor is configured to determine trend data associated with the pre-ejection period, the left ventricular ejection time and a ratio of the pre-ejection period and the left ventricular ejection time for a plurality of the sensed cardiac events, determine whether the pre-ejection period is increasing, determine whether the left ventricular ejection time is decreasing, determine whether the ratio of the pre-ejection period and the left ventricular ejection time is increasing, determine whether heart failure is indicated in response to determining at least two of the pre-ejection period determined to be increasing, the left ventricular ejection time determined to be decreasing, and the ratio of the pre-ejection period and the left ventricular ejection time determined to be increasing, and generate an alert in response to heart failure being indicated.
- The device of any of embodiments 11-16, wherein determining whether the pre-ejection period increases comprises one of determining whether the pre-ejection period increases by greater than a predetermined percentage over a predetermined number of days and determining whether the pre-ejection period increases above a predetermined numerical threshold, wherein determining whether the left ventricular ejection time decreases comprises one of determining whether the left ventricular ejection time decreases by greater than a predetermined percentage over a predetermined number of days and determining whether the left ventricular ejection time decreases above a predetermined numerical threshold, and wherein determining whether the ratio of the pre-ejection period increases comprises one of determining whether the ratio of the pre-ejection period and the left ventricular ejection time increases by greater than a predetermined percentage over a predetermined number of days and determining whether the ratio of the pre-ejection period and the left ventricular ejection time increases above a predetermined numerical threshold.
- The device of any of embodiments 11-17, wherein the processor is configured to determine trend data associated with the pre-ejection period, the left ventricular ejection time and a ratio of the pre-ejection period and the left ventricular ejection time for a plurality of the sensed cardiac events, determine whether the pre-ejection period is increasing, determine whether the left ventricular ejection time is decreasing; determine whether the ratio of the pre-ejection period and the left ventricular ejection time is increasing, determine whether heart failure is indicated in response to determining at least two of the pre-ejection period determined to be increasing, the left ventricular ejection time determined to be decreasing, and the ratio of the pre-ejection period and the left ventricular ejection time determined to be increasing, adjust delivery of the cardiac pacing therapy in response to one of determining the pre-ejection period is increasing and determining the ratio of the pre-ejection period and the left ventricular ejection time is increasing, and generate an alert in response to heart failure being indicated.
- The device of any of embodiments 11-18, wherein determining whether the pre-ejection period increases comprises one of determining whether the pre-ejection period increases by greater than a predetermined percentage over a predetermined number of days and determining whether the pre-ejection period increases above a predetermined numerical threshold, wherein determining whether the left ventricular ejection time decreases comprises one of determining whether the left ventricular ejection time decreases by greater than a predetermined percentage over a predetermined number of days and determining whether the left ventricular ejection time decreases above a predetermined numerical threshold, and wherein determining whether the ratio of the pre-ejection period increases comprises one of determining whether the ratio of the pre-ejection period and the left ventricular ejection time increases by greater than a predetermined percentage over a predetermined number of days and determining whether the ratio of the pre-ejection period and the left ventricular ejection time increases above a predetermined numerical threshold.
- The device of any of embodiments 11-19, wherein the cardiac pacing device comprises a leadless pacemaker device and the sensed pacing event comprises a ventricular pacing event.
- A non-transitory computer readable medium storing instructions which cause a cardiac medical device to perform a method comprising:
-
- delivering the cardiac pacing therapy from a cardiac pacing device;
- sensing a pacing event from a plurality of electrodes of the pacing device;
- sensing an electromechanical signal from an electromechanical sensor of the pacing device;
- determining a pre-ejection period in response to the sensed electromechanical signal;
- determining a left ventricular ejection time in response to the sensed electromechanical signal; and
- performing one or both of adjusting a pacing parameter setting and generating an alert in response to the determined pre-ejection period and the determined left ventricular ejection time.
- A medical device system comprising means to perform the method of any one of claims 1-10.
- A computer-readable storage medium comprising instructions that, when executed by processing circuitry of a medical device system, cause the processing circuitry to perform the method of any of claims 1-10.
Claims (24)
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/903,550 US20190262617A1 (en) | 2018-02-23 | 2018-02-23 | Generation of diagnostic metrics for use in determining delivery of pacing therapy by a cardiac pacing device |
EP19708727.3A EP3755428B1 (en) | 2018-02-23 | 2019-02-14 | Generation of diagnostic metrics for use in determining delivery of pacing therapy by a cardiac pacing device |
CN201980014821.1A CN111741793A (en) | 2018-02-23 | 2019-02-14 | Generating diagnostic metrics for use in determining pacing therapy delivery by a cardiac pacing device |
PCT/US2019/018033 WO2019164747A1 (en) | 2018-02-23 | 2019-02-14 | Generation of diagnostic metrics for use in determining delivery of pacing therapy by a cardiac pacing device |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/903,550 US20190262617A1 (en) | 2018-02-23 | 2018-02-23 | Generation of diagnostic metrics for use in determining delivery of pacing therapy by a cardiac pacing device |
Publications (1)
Publication Number | Publication Date |
---|---|
US20190262617A1 true US20190262617A1 (en) | 2019-08-29 |
Family
ID=65635822
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/903,550 Abandoned US20190262617A1 (en) | 2018-02-23 | 2018-02-23 | Generation of diagnostic metrics for use in determining delivery of pacing therapy by a cardiac pacing device |
Country Status (4)
Country | Link |
---|---|
US (1) | US20190262617A1 (en) |
EP (1) | EP3755428B1 (en) |
CN (1) | CN111741793A (en) |
WO (1) | WO2019164747A1 (en) |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5156154A (en) * | 1991-03-08 | 1992-10-20 | Telectronics Pacing Systems, Inc. | Monitoring the hemodynamic state of a patient from measurements of myocardial contractility using doppler ultrasound techniques |
US7569020B2 (en) * | 2006-06-19 | 2009-08-04 | St. Jude Medical Ab | Method for extracting timing parameters using a cardio-mechanical sensor |
US8364263B2 (en) * | 2006-10-26 | 2013-01-29 | Cardiac Pacemakers, Inc. | System and method for systolic interval analysis |
US9770584B2 (en) * | 2014-05-29 | 2017-09-26 | Cardiac Pacemakers, Inc. | System and methods for treating atrial fibrillation using hemodynamic responses |
US9694186B2 (en) * | 2014-09-08 | 2017-07-04 | Medtronic, Inc. | Dual chamber timing for leadless pacemakers using infrequent atrial signals and ventricular contractions |
US9789320B2 (en) * | 2014-10-17 | 2017-10-17 | Cardiac Pacemakers, Inc. | Method and apparatus for ambulatory optimization of multi-site pacing using heart sounds |
-
2018
- 2018-02-23 US US15/903,550 patent/US20190262617A1/en not_active Abandoned
-
2019
- 2019-02-14 WO PCT/US2019/018033 patent/WO2019164747A1/en unknown
- 2019-02-14 CN CN201980014821.1A patent/CN111741793A/en active Pending
- 2019-02-14 EP EP19708727.3A patent/EP3755428B1/en active Active
Also Published As
Publication number | Publication date |
---|---|
CN111741793A (en) | 2020-10-02 |
EP3755428A1 (en) | 2020-12-30 |
EP3755428B1 (en) | 2023-10-11 |
WO2019164747A1 (en) | 2019-08-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11305126B2 (en) | Atrial tracking in an intracardiac ventricular pacemaker | |
CN109789309B (en) | Atrial tracking in an intracardiac ventricular pacemaker | |
CN109937070B (en) | Atrial tracking in an intracardiac ventricular pacemaker | |
US9694186B2 (en) | Dual chamber timing for leadless pacemakers using infrequent atrial signals and ventricular contractions | |
EP3191180B1 (en) | Far-field r-wave detection to control atrial pace timing in a leadless pacemaker | |
US10512424B2 (en) | Method and apparatus for selecting activity response vector | |
US20230226360A1 (en) | Rate smoothing to enhance atrial synchronous pacing in a ventricular pacemaker | |
EP3773884B1 (en) | Pacing mode switching and rate response limit in a ventricular pacemaker | |
EP2632540B1 (en) | Pacing interval determination for ventricular dyssynchrony | |
CN110831659B (en) | Atrial tracking validation in an intracardiac ventricular pacemaker | |
CN111565795A (en) | Adaptive cardiac resynchronization therapy | |
CN114286707A (en) | Cardiac resynchronization therapy mode switching using mechanical activity | |
EP4074374A1 (en) | Rate smoothing in atrial synchronous ventricular pacemaker | |
EP3755428B1 (en) | Generation of diagnostic metrics for use in determining delivery of pacing therapy by a cardiac pacing device | |
US9789318B2 (en) | Method and apparatus for optimizing multi-site pacing using heart sounds | |
CN111770724B (en) | Capture management in leadless cardiac pacing devices | |
CN111629780A (en) | Cardiac resynchronization therapy diagnosis | |
US20230263416A1 (en) | Method and apparatus for determining heart rate | |
WO2023156895A1 (en) | Apparatus for determining heart rate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: MEDTRONIC, INC., MINNESOTA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:GHOSH, SUBHAM;REEL/FRAME:045733/0739 Effective date: 20180223 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STCV | Information on status: appeal procedure |
Free format text: NOTICE OF APPEAL FILED |
|
STCV | Information on status: appeal procedure |
Free format text: APPEAL BRIEF (OR SUPPLEMENTAL BRIEF) ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCV | Information on status: appeal procedure |
Free format text: NOTICE OF APPEAL FILED |
|
STCV | Information on status: appeal procedure |
Free format text: APPEAL BRIEF (OR SUPPLEMENTAL BRIEF) ENTERED AND FORWARDED TO EXAMINER |
|
STCV | Information on status: appeal procedure |
Free format text: EXAMINER'S ANSWER TO APPEAL BRIEF MAILED |
|
STCV | Information on status: appeal procedure |
Free format text: ON APPEAL -- AWAITING DECISION BY THE BOARD OF APPEALS |
|
STCV | Information on status: appeal procedure |
Free format text: BOARD OF APPEALS DECISION RENDERED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- AFTER EXAMINER'S ANSWER OR BOARD OF APPEALS DECISION |